How direct-to-patient clinical trial models can accelerate speed-to-market
Analyzing the benefits and challenges of implementing direct-to-patient services in the clinical supply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market
Add bookmark
The uncertainty raised by the Covid-19 pandemic has forced the pharma industry to turn its resources toward strengthening clinical trial supply chains and improving patient access to care. In doing so, the industry has deepened its focus on patient-centricity and has expanded treatment options available for unknown diseases.
In this light, Pharma IQ has collaborated with PCI to explore the benefits, challenges and solutions of implementing direct-to-patient (DtP) supply chains in clinical trial settings, so that sponsors can streamline processes and increase speed to market, without compromising trial integrity or quality.
Share best practice, ideas, and solutions to our global community of more than 125,000 senior pharmaceutical and biotech professionals. View our latest Media Kit to learn more about our audience and review our content calendar. Download NowInterested in presenting your own Case Study?
Download the report to receive exclusive expert-led insights and discover:
- The importance of DtP services in the modern clinical trial delivery.
- The benefits of developing a patient-centric clinical supply chain.
- Best practices for connecting patients with an end-to-end solution.
- How to drive the future of the DtP model to advance your clinical supply chain.
